Febrile Neutropenia - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Febrile Neutropenia - Pipeline Review, H2 2016’, provides an overview of the Febrile Neutropenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Febrile Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Febrile Neutropenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Febrile Neutropenia

The report reviews pipeline therapeutics for Febrile Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Febrile Neutropenia therapeutics and enlists all their major and minor projects

The report assesses Febrile Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Febrile Neutropenia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Febrile Neutropenia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Febrile Neutropenia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Apotex Inc.

BeyondSpring Pharmaceuticals, Inc.

Biogenomics Limited

Coherus BioSciences, Inc.

Dr. Reddy's Laboratories Limited

Richter Gedeon Nyrt.

Sandoz International GmbH

Therapeutic Proteins International, LLC

USV ...

Apotex Inc.

BeyondSpring Pharmaceuticals, Inc.

Biogenomics Limited

Coherus BioSciences, Inc.

Dr. Reddy's Laboratories Limited

Richter Gedeon Nyrt.

Sandoz International GmbH

Therapeutic Proteins International, LLC

USV Pvt Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Febrile Neutropenia ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Febrile Neutropenia Overview 7

Therapeutics Development 8

Pipeline Products for Febrile Neutropenia - Overview 8

Febrile Neutropenia - Therapeutics under Development by Companies 9

Febrile Neutropenia - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Unknown Stage Products 14

Febrile Neutropenia - Products under Development by Companies 15

Febrile Neutropenia - Companies Involved in Therapeutics Development 16

Apotex Inc. 16

BeyondSpring Pharmaceuticals, Inc. 17

Biogenomics Limited 18

Coherus BioSciences, Inc. 19

Dr. Reddy's Laboratories Limited 20

Richter Gedeon Nyrt. 21

Sandoz International GmbH 22

Therapeutic Proteins International, LLC 23

USV Pvt Ltd 24

Febrile Neutropenia - Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

EC-18 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

filgrastim - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

filgrastim - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

filgrastim - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

pegfilgrastim - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

pegfilgrastim - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

pegfilgrastim - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

pegfilgrastim - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

pegfilgrastim - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

pegfilgrastim - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

pegfilgrastim - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

pegfilgrastim - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

pegfilgrastim - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

pegfilgrastim - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

plinabulin - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Febrile Neutropenia - Dormant Projects 53

Febrile Neutropenia - Product Development Milestones 54

Featured News & Press Releases 54

Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study 54

Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim 55

Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study 55

Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701 56

Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program 56

Dec 08, 2015: EMA started the evaluation of Richter’s marketing authorisation application for biosimilar pegfilgrastim 57

Nov 18, 2015: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA 57

Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study 58

Appendix 59

Methodology 59

Coverage 59

Secondary Research 59

Primary Research 59

Expert Panel Validation 59

Contact Us 59

Disclaimer 60

List of Tables

List of Tables

Number of Products under Development for Febrile Neutropenia, H2 2016 8

Number of Products under Development by Companies, H2 2016 10

Comparative ...

List of Tables

Number of Products under Development for Febrile Neutropenia, H2 2016 8

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Comparative Analysis by Unknown Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Febrile Neutropenia - Pipeline by Apotex Inc., H2 2016 16

Febrile Neutropenia - Pipeline by BeyondSpring Pharmaceuticals, Inc., H2 2016 17

Febrile Neutropenia - Pipeline by Biogenomics Limited, H2 2016 18

Febrile Neutropenia - Pipeline by Coherus BioSciences, Inc., H2 2016 19

Febrile Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 20

Febrile Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2016 21

Febrile Neutropenia - Pipeline by Sandoz International GmbH, H2 2016 22

Febrile Neutropenia - Pipeline by Therapeutic Proteins International, LLC, H2 2016 23

Febrile Neutropenia - Pipeline by USV Pvt Ltd, H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Stage and Target, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33

Febrile Neutropenia - Dormant Projects, H2 2016 53

List of Figures

List of Figures

Number of Products under Development for Febrile Neutropenia, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative ...

List of Figures

Number of Products under Development for Febrile Neutropenia, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Targets, H2 2016 26

Number of Products by Stage and Targets, H2 2016 26

Number of Products by Mechanism of Actions, H2 2016 28

Number of Products by Stage and Mechanism of Actions, H2 2016 28

Number of Products by Routes of Administration, H2 2016 30

Number of Products by Stage and Routes of Administration, H2 2016 30

Number of Products by Molecule Types, H2 2016 32

Number of Products by Stage and Molecule Types, H2 2016 32

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports